^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Truxima (rituximab-abbs)

    i
    Other names: CT-P10, TL011, TL 011
    Company:
    Celltrion, Indukern, Mundipharma, Nippon Kayaku, Teva
    Drug class:
    CD20 inhibitor
    Related drugs:
    22h
    RG1716009: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, University of Washington | Trial completion date: Jan 2031 --> Jan 2028
    Trial completion date
    |
    Rituxan (rituximab) • Ninlaro (ixazomib) • Truxima (rituximab-abbs)
    2d
    UCDCC#303: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=24, Recruiting, University of California, Davis | Trial primary completion date: Feb 2026 --> Oct 2026
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Zynlonta (loncastuximab tesirine-lpyl) • Truxima (rituximab-abbs)
    9d
    Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study (clinicaltrials.gov)
    P2, N=43, Not yet recruiting, AIDS Malignancy Consortium
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    LDH elevation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    10d
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) (clinicaltrials.gov)
    P2/3, N=960, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD)
    10d
    CA123-1000: A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1/2, N=460, Recruiting, Bristol-Myers Squibb | N=308 --> 460
    Enrollment change
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)
    10d
    Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    10d
    Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    15d
    The CARDIOPROTECT Trial (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Beth Israel Deaconess Medical Center
    New P2 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • Truxima (rituximab-abbs) • Myocet (non-pegylated liposomal doxorubicin) • Polivy (polatuzumab vedotin-piiq) • dexrazoxane
    16d
    AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Mabtas (rituximab biosimilar)
    21d
    RIGA: Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis (clinicaltrials.gov)
    P3, N=75, Completed, Hopital Foch | Active, not recruiting --> Completed | Trial primary completion date: Jul 2025 --> Jan 2026
    Trial completion • Trial primary completion date
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)
    21d
    Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial (clinicaltrials.gov)
    P3, N=102, Not yet recruiting, SWOG Cancer Research Network | Initiation date: May 2026 --> Aug 2026
    Trial initiation date
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • Jaypirca (pirtobrutinib) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Mabtas (rituximab biosimilar)
    21d
    NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • gemcitabine • Rituxan (rituximab) • oxaliplatin • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)